PH12021551165A1 - Glp-1r agonists and uses thereof - Google Patents

Glp-1r agonists and uses thereof

Info

Publication number
PH12021551165A1
PH12021551165A1 PH12021551165A PH12021551165A PH12021551165A1 PH 12021551165 A1 PH12021551165 A1 PH 12021551165A1 PH 12021551165 A PH12021551165 A PH 12021551165A PH 12021551165 A PH12021551165 A PH 12021551165A PH 12021551165 A1 PH12021551165 A1 PH 12021551165A1
Authority
PH
Philippines
Prior art keywords
glp
agonists
diabetes
obesity
compounds
Prior art date
Application number
PH12021551165A
Inventor
Wenge Zhong
Original Assignee
Qilu Regor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70774321&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12021551165(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Qilu Regor Therapeutics Inc filed Critical Qilu Regor Therapeutics Inc
Publication of PH12021551165A1 publication Critical patent/PH12021551165A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Provided are compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.
PH12021551165A 2018-11-22 2021-05-21 Glp-1r agonists and uses thereof PH12021551165A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018117047 2018-11-22
PCT/CN2019/119373 WO2020103815A1 (en) 2018-11-22 2019-11-19 Glp-1r agonists and uses thereof

Publications (1)

Publication Number Publication Date
PH12021551165A1 true PH12021551165A1 (en) 2021-10-25

Family

ID=70774321

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12021551165A PH12021551165A1 (en) 2018-11-22 2021-05-21 Glp-1r agonists and uses thereof

Country Status (23)

Country Link
US (3) US12365670B2 (en)
EP (1) EP3883928A4 (en)
JP (1) JP7664156B2 (en)
KR (1) KR102904955B1 (en)
CN (1) CN113227068B (en)
AU (1) AU2019382642B2 (en)
BR (1) BR112021009877A2 (en)
CA (1) CA3120499A1 (en)
CL (1) CL2021001332A1 (en)
CO (1) CO2021008089A2 (en)
CR (1) CR20210341A (en)
CU (1) CU20210042A7 (en)
EA (1) EA202191432A1 (en)
IL (1) IL283322B2 (en)
MA (1) MA54555A (en)
MX (1) MX2021006034A (en)
PE (1) PE20211871A1 (en)
PH (1) PH12021551165A1 (en)
SA (1) SA521422068B1 (en)
SG (1) SG11202105241YA (en)
TW (1) TWI839416B (en)
UA (1) UA130273C2 (en)
WO (1) WO2020103815A1 (en)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202011704XA (en) * 2018-06-15 2020-12-30 Pfizer Glp-1 receptor agonists and uses thereof
AU2019322538B2 (en) 2018-08-13 2021-09-30 F. Hoffmann-La Roche Ag New heterocyclic compounds as monoacylglycerol lipase inhibitors
CU20210042A7 (en) 2018-11-22 2022-01-13 Qilu Regor Therapeutics Inc Glp-1r agonists
BR112021020335A2 (en) * 2019-04-12 2021-12-14 Qilu Regor Therapeutics Inc glp-1r agonists and uses thereof
TWI751585B (en) 2019-06-28 2022-01-01 美商美國禮來大藥廠 Glucagon-like peptide 1 receptor agonists
WO2021018023A1 (en) * 2019-08-01 2021-02-04 济南泰达领创医药技术有限公司 Small molecule glp-1 receptor modulator
MX2022002311A (en) 2019-09-12 2022-03-25 Hoffmann La Roche 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors.
PE20221040A1 (en) * 2019-10-25 2022-06-17 Gilead Sciences Inc GLP-1R MODULATING COMPOUNDS
MA57692B1 (en) 2019-11-15 2025-04-30 Ildong Pharmaceutical Co., Ltd. GLP-1 RECEPTOR AGONIST AND ITS USE
CA3168543A1 (en) 2020-01-29 2021-08-05 Gilead Sciences, Inc. Glp-1r modulating compounds
PE20231066A1 (en) 2020-02-07 2023-07-17 Gasherbrum Bio Inc GLP-1 HETEROCYCLIC AGONISTS
JP7836762B2 (en) * 2020-02-13 2026-03-27 ガシャーブラム・バイオ・インコーポレイテッド Heterocyclic GLP-1 agonist
TW202144340A (en) * 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 Fused imidazole derivatives, preparation method and medical use thereof
EP4143183B1 (en) 2020-04-29 2025-10-22 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
PL4157832T3 (en) * 2020-05-27 2024-12-16 Qilu Regor Therapeutics Inc. Salt and crystal forms of glp-1r agonists and uses thereof
EP4155313B1 (en) * 2020-06-04 2025-08-27 Hangzhou Sciwind Biosciences Co., Ltd. Five-membered heteroaromatic imidazole compound and use thereof
CN113773310B (en) * 2020-06-10 2023-12-22 重庆康丁医药技术有限公司 GLP-1 small molecule with cardiovascular benefit
CN113816948B (en) * 2020-06-19 2023-08-11 江苏恒瑞医药股份有限公司 Condensed imidazole derivative, preparation method and medical application thereof
WO2021259309A1 (en) * 2020-06-24 2021-12-30 广州市恒诺康医药科技有限公司 Glp-1 receptor agonist, and pharmaceutical composition and use thereof
TW202214622A (en) * 2020-08-06 2022-04-16 大陸商上海齊魯銳格醫藥研發有限公司 Glp-1r agonists and uses thereof
WO2022028572A1 (en) 2020-08-06 2022-02-10 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
KR20230074486A (en) * 2020-08-21 2023-05-30 테른스 파마슈티칼스, 인크. Compounds as GLP-1R agonists
CN116406360A (en) 2020-08-28 2023-07-07 加舒布鲁姆生物公司 Heterocyclic GLP-1 agonists
CN119930605A (en) 2020-09-01 2025-05-06 江苏恒瑞医药股份有限公司 Condensed imidazole derivatives, preparation methods thereof and their application in medicine
MX2023002691A (en) * 2020-09-03 2023-05-03 Amgen Inc Diol desymmetrization by nucleophilic aromatic substitution.
JP7858636B2 (en) 2020-09-10 2026-05-14 ガシャーブラム・バイオ・インコーポレイテッド Heterocyclic GLP-1 agonist
WO2022068772A1 (en) * 2020-09-29 2022-04-07 深圳信立泰药业股份有限公司 Benzimidazole derivative, and preparation method therefor, and medical use thereof
CN116348464A (en) * 2020-10-12 2023-06-27 杭州中美华东制药有限公司 Benzimidazolone GLP-1 receptor agonists and uses thereof
CN116547279A (en) * 2020-10-13 2023-08-04 加舒布鲁姆生物公司 Heterocyclic GLP-1 agonists
CN116547278A (en) * 2020-10-13 2023-08-04 加舒布鲁姆生物公司 Heterocyclic GLP-1 agonists
WO2022078352A1 (en) * 2020-10-14 2022-04-21 Qilu Regor Therapeutics Inc. Crystal forms of glp-1r agonists and uses thereof
CN114478497B (en) * 2020-11-12 2023-10-20 杭州中美华东制药有限公司 Arylalkyl acid GLP-1 receptor agonists and uses thereof
WO2022109182A1 (en) * 2020-11-20 2022-05-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
CA3200245A1 (en) * 2020-11-27 2022-06-02 Junjun Wu Benzimidazole derivative and preparation method therefor and medical use thereof
CN114591308B (en) * 2020-12-03 2024-03-08 苏州闻泰医药科技有限公司 A class of GLP-1R receptor agonist compounds and their uses
AU2021405918A1 (en) * 2020-12-25 2023-07-20 Xizang Haisco Pharmaceutical Co., Ltd. Five-membered ring derivative and medical use thereof
CN117043154A (en) * 2021-01-28 2023-11-10 卡莫特医疗有限公司 GPCR receptor agonists, pharmaceutical compositions containing the same, and methods of using the same
MX2023008854A (en) * 2021-01-28 2023-10-17 Carmot Therapeutics Inc Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use.
CN114907351A (en) * 2021-02-07 2022-08-16 杭州中美华东制药有限公司 Tricyclic GLP-1 receptor agonists and uses thereof
WO2022184849A1 (en) 2021-03-04 2022-09-09 Les Laboratoires Servier Glp-1r agonists, uses and pharmaceutical compositions thereof
EP4304711A1 (en) * 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
WO2022192430A1 (en) * 2021-03-11 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
CN116940561A (en) * 2021-03-22 2023-10-24 杭州中美华东制药有限公司 Thiophene GLP-1 receptor agonist and application thereof
JP7772778B2 (en) 2021-03-24 2025-11-18 塩野義製薬株式会社 Pharmaceutical composition containing a GLP-1 receptor agonist having a fused ring
PL4271672T3 (en) 2021-04-21 2026-04-20 Gilead Sciences, Inc. Carboxy-benzimidazole glp-1r modulating compounds
WO2022228490A1 (en) * 2021-04-30 2022-11-03 上海翰森生物医药科技有限公司 Polycyclic derivative modulator, and preparation method therefor and use thereof
EP4334304A1 (en) * 2021-05-03 2024-03-13 Carmot Therapeutics, Inc. Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use
TWI843104B (en) 2021-05-20 2024-05-21 美商美國禮來大藥廠 Glucagon-like peptide 1 receptor agonists
MX2023014985A (en) * 2021-06-24 2024-02-14 Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd GLP-1 RECEPTOR AGONIST AND COMPOSITION AND USE THEREOF.
JP2024525900A (en) * 2021-07-21 2024-07-12 ヘパジーン セラピューティクス（エイチケー）リミティド Glucagon-like peptide-1 receptor modulators and uses thereof
CN113480534B (en) * 2021-07-23 2022-05-13 广州必贝特医药股份有限公司 Benzimidazole or azabenzimidazole-6-carboxylic acid compounds and application thereof
US20240360109A1 (en) * 2021-08-04 2024-10-31 Shanghai Hansoh Biomedical Co., Ltd. Cycloalkene derivative regulator, preparation method therefor, and application thereof
WO2023029380A1 (en) 2021-08-30 2023-03-09 杭州德睿智药科技有限公司 Novel aryl ether substituted heterocyclic compound as glp1r agonist
AU2022344074A1 (en) 2021-09-08 2024-02-29 Shionogi & Co., Ltd. Medicine for prevention and treatment of diseases linked to anti-obesity activity
FI4408840T3 (en) 2021-09-27 2025-11-04 Terns Pharmaceuticals Inc BENZIMIDAZOLE CARBOXYLIC ACIDS AS GLP-1R AGONISTS
WO2023057429A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
WO2023057414A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
EP4412707A1 (en) 2021-10-05 2024-08-14 Astrazeneca AB Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators
TWI843243B (en) * 2021-10-22 2024-05-21 大陸商盛世泰科生物醫藥技術（蘇州）股份有限公司 Compounds as glp-1 receptor agonist, pharmaceutical composition including the same and use thereof
IL312364A (en) * 2021-10-25 2024-06-01 Luehr Gary W Compounds as glp-1r agonists
EP4441047A4 (en) * 2021-12-03 2025-03-19 Hangzhou Sciwind Biosciences Co., Ltd. CRYSTALLINE FORMS OF A THIENOIMIDAZOLE COMPOUND AND PRODUCTION PROCESS THEREOF
CN114163438A (en) * 2021-12-13 2022-03-11 无锡捷化医药科技有限公司 Preparation method of 2-methyl-3-carbonyl pyrazolo [4,3-c ] pyridine-7-carboxylic acid hydrochloride
US20250066338A1 (en) 2021-12-16 2025-02-27 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
US20250042882A1 (en) 2021-12-16 2025-02-06 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
EP4455141B1 (en) * 2021-12-23 2026-03-25 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutically acceptable salt and crystalline form of a glp-1 receptor agonist for the treatment of diabetes
CN116354945B (en) * 2021-12-27 2024-08-30 长春金赛药业有限责任公司 Fused imidazole carboxylic acid compound and preparation method and application thereof
WO2023130878A1 (en) * 2022-01-10 2023-07-13 海思科医药集团股份有限公司 Glp-1 agonist salt, and crystal form and medical use thereof
JP2025506474A (en) * 2022-02-09 2025-03-11 ガシャーブラム・バイオ・インコーポレイテッド Heterocyclic GLP-1 agonists
US12410163B2 (en) 2022-02-23 2025-09-09 Terns Pharmaceuticals, Inc. Compounds as GLP-IR agonists
CA3245508A1 (en) 2022-03-08 2025-01-22 Guangzhou Unirise Pharmaceutical Co., Ltd. Benzobicyclic compounds, preparation methods and use thereof
JP2025509281A (en) * 2022-03-09 2025-04-11 ガシャーブラム・バイオ・インコーポレイテッド Heterocyclic GLP-1 agonists
EP4508047A1 (en) * 2022-04-14 2025-02-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2023222084A1 (en) * 2022-05-20 2023-11-23 成都地奥九泓制药厂 Benzimidazole or azabenzimidazole compound, preparation method therefor and use thereof
CN117362282B (en) * 2022-07-07 2026-04-21 杭州德睿智药科技有限公司 Salts of GLP-1R agonists, their preparation methods and applications
WO2024026338A1 (en) * 2022-07-27 2024-02-01 Carmot Therapeutics, Inc. N-heterocylic gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use
MX2025002598A (en) * 2022-09-06 2025-05-02 Mindrank Therapeutics Suzhou New Drug Res And Development Co Ltd Polymorph of glp-1r agonist compound, preparation method therefor, and use thereof
EP4592285A1 (en) 2022-09-22 2025-07-30 Shionogi & Co., Ltd. Fused ring compound having glp-1 receptor agonist effect
CN116102543B (en) * 2022-10-21 2025-07-22 江南大学 GLP-1R agonist, synthesis method and application thereof
KR20250105662A (en) 2022-11-11 2025-07-08 일라이 릴리 앤드 캄파니 Glucagon-like peptide 1 receptor agonist
EP4619098A1 (en) 2022-11-16 2025-09-24 Eli Lilly and Company Glucagon-like peptide 1 receptor agonists
WO2024125442A1 (en) * 2022-12-13 2024-06-20 杭州中美华东制药有限公司 Novel crystal form of glp-1 receptor agonist, method for preparing same, pharmaceutical composition thereof, and use thereof
AU2023394509A1 (en) * 2022-12-13 2025-07-10 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Salt-type glp-1 receptor agonist, crystal form thereof, preparation method therefor, pharmaceutical composition thereof, and use thereof
AU2024210933A1 (en) * 2023-01-17 2025-08-07 Fochon Biosciences, Ltd. Glp-1r agonists and uses thereof
AU2024213693A1 (en) * 2023-02-02 2025-09-11 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Salt and crystal form of cycloalkene compound, and preparation method therefor and use thereof
IL322686A (en) 2023-02-16 2025-10-01 Gasherbrum Bio Inc Heterocyclic glp-1 agonists
WO2024211898A1 (en) 2023-04-07 2024-10-10 Terns Pharmaceuticals, Inc. Combination comprising a thrbeta agonist anda glp-1r agonist for use in treating a liver disorder or a cardiometabolic disease
WO2024212742A1 (en) * 2023-04-10 2024-10-17 上海研健新药研发有限公司 Glp-1r agonist, preparation method therefor and use thereof
TW202504600A (en) * 2023-07-04 2025-02-01 大陸商杭州中美華東製藥有限公司 Preparation method of glp1r agonist and intermediate thereof
AU2024340407A1 (en) 2023-09-14 2026-04-23 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss
KR20260038229A (en) * 2024-09-11 2026-03-18 한미약품 주식회사 GLP-1 receptor agonist and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US20040127504A1 (en) 2002-09-06 2004-07-01 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
JP2006525366A (en) 2003-04-30 2006-11-09 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー Heterocyclic carboxylic acid substituent
NZ553696A (en) 2004-09-13 2010-02-26 Ono Pharmaceutical Co Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
AU2005307718A1 (en) 2004-11-18 2006-05-26 The Institutes For Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids for the treatment of diabetes
EP1976873A2 (en) 2006-01-11 2008-10-08 Brystol-Myers Squibb Company Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
KR101616737B1 (en) 2008-03-07 2016-05-02 브이티브이 테라퓨틱스 엘엘씨 Oxadiazoanthracene compounds for the treatment of diabetes
US8765920B2 (en) 2009-12-23 2014-07-01 The Scripps Research Institute Tyrosine bioconjugation through aqueous Ene-like reactions
NZ603876A (en) * 2010-05-13 2015-02-27 Amgen Inc Nitrogen heterocyclic compounds useful as pde10 inhibitors
JP2013530963A (en) 2010-06-09 2013-08-01 レセプトス インコーポレイテッド Novel GLP-1 receptor stabilizers and modulators
MX348131B (en) 2011-02-25 2017-05-26 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents.
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
ES2836973T3 (en) 2011-12-12 2021-06-28 Receptos Llc Carboxylic acid derivatives comprising four cycles that act as GLP-1 receptor modulators for the therapy of diseases such as diabetes
PL3240785T3 (en) 2014-12-29 2021-12-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Small molecule inhibitors of lactate dehydrogenase and methods of use thereof
EP3429591B1 (en) 2016-03-16 2023-03-15 Kura Oncology, Inc. Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use
CN110325530B (en) 2016-12-16 2022-01-11 辉瑞大药厂 GLP-1 receptor agonists and uses thereof
US10934279B2 (en) * 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
SG11202011704XA (en) * 2018-06-15 2020-12-30 Pfizer Glp-1 receptor agonists and uses thereof
US11945803B2 (en) 2018-08-07 2024-04-02 Tosk, Inc. Modulators of RAS GTPase
BR112021003039A2 (en) 2018-08-31 2021-05-18 Pfizer Inc. combinations for the treatment of nash/nafld and related diseases
CU20210042A7 (en) * 2018-11-22 2022-01-13 Qilu Regor Therapeutics Inc Glp-1r agonists
BR112021020335A2 (en) 2019-04-12 2021-12-14 Qilu Regor Therapeutics Inc glp-1r agonists and uses thereof
TWI751585B (en) 2019-06-28 2022-01-01 美商美國禮來大藥廠 Glucagon-like peptide 1 receptor agonists
WO2021018023A1 (en) 2019-08-01 2021-02-04 济南泰达领创医药技术有限公司 Small molecule glp-1 receptor modulator
PE20221040A1 (en) 2019-10-25 2022-06-17 Gilead Sciences Inc GLP-1R MODULATING COMPOUNDS
EP4069686B1 (en) 2019-12-02 2025-01-22 Hyundai Pharm Co., Ltd. Glp-1 receptor agonist
WO2021116874A1 (en) 2019-12-10 2021-06-17 Pfizer Inc. Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d] [1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d] imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt
CA3168543A1 (en) 2020-01-29 2021-08-05 Gilead Sciences, Inc. Glp-1r modulating compounds
PE20231066A1 (en) 2020-02-07 2023-07-17 Gasherbrum Bio Inc GLP-1 HETEROCYCLIC AGONISTS
JP7836762B2 (en) 2020-02-13 2026-03-27 ガシャーブラム・バイオ・インコーポレイテッド Heterocyclic GLP-1 agonist
IL296694A (en) 2020-03-27 2022-11-01 Pfizer Treatment of type 2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
EP4141008A4 (en) 2020-04-01 2024-04-17 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. PHARMACEUTICALLY ACCEPTABLE ACID SALT OF THE FREE BASE OF A GLP-1 RECEPTOR AGONIST AND METHOD OF MANUFACTURING THE SAME
JP2023528565A (en) 2020-04-01 2023-07-05 ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． Crystal Form A of GLP-1 Receptor Agonist and Method for Preparing The Same
TW202144340A (en) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 Fused imidazole derivatives, preparation method and medical use thereof
CN113493447B (en) 2020-04-03 2024-06-11 轩竹(北京)医药科技有限公司 GLP-1 receptor agonists
PL4157832T3 (en) * 2020-05-27 2024-12-16 Qilu Regor Therapeutics Inc. Salt and crystal forms of glp-1r agonists and uses thereof

Also Published As

Publication number Publication date
AU2019382642A1 (en) 2021-06-10
JP7664156B2 (en) 2025-04-17
EP3883928A1 (en) 2021-09-29
EP3883928A4 (en) 2022-06-29
IL283322A (en) 2021-07-29
US20200283424A1 (en) 2020-09-10
TW202039458A (en) 2020-11-01
WO2020103815A1 (en) 2020-05-28
IL283322B2 (en) 2025-08-01
US10844049B2 (en) 2020-11-24
BR112021009877A2 (en) 2021-08-17
SG11202105241YA (en) 2021-06-29
CU20210042A7 (en) 2022-01-13
CA3120499A1 (en) 2020-05-28
CL2021001332A1 (en) 2021-11-05
CN113227068A (en) 2021-08-06
JP2022508203A (en) 2022-01-19
MX2021006034A (en) 2021-09-21
CO2021008089A2 (en) 2021-09-09
CN113227068B (en) 2023-06-13
UA130273C2 (en) 2026-01-07
EA202191432A1 (en) 2021-10-14
IL283322B1 (en) 2025-04-01
CR20210341A (en) 2021-11-25
US20220024901A1 (en) 2022-01-27
TWI839416B (en) 2024-04-21
AU2019382642B2 (en) 2025-05-29
US12365670B2 (en) 2025-07-22
KR20210106447A (en) 2021-08-30
US20260035362A1 (en) 2026-02-05
KR102904955B1 (en) 2025-12-30
MA54555A (en) 2021-09-29
PE20211871A1 (en) 2021-09-21
SA521422068B1 (en) 2024-04-24

Similar Documents

Publication Publication Date Title
CR20210341A (en) Glp-1r agonists and uses thereof
PH12021552557A1 (en) Glp-1r agonists and uses thereof
AR123156A1 (en) GLP-1R AGONISTS AND THEIR USES
CY1123591T1 (en) COMPOUNDS OF GLUCAGON AND GLP-1 COMPETITORS
UA88104C2 (en) Pyridazinone derivatives as thyroid hormone receptor agonists
EP4578460A3 (en) Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
MX2023008330A (en) Compositions and methods for the treatment of metabolic and liver disorders.
MX2018005193A (en) Dual function proteins and pharmaceutical composition comprising same.
MY189770A (en) Biaryl derivative as gpr120 agonists
CL2008000020A1 (en) Compounds derived from substituted 2,4-dianilinopyrimidines, protein kinase inhibitors; preparation procedure; pharmaceutical composition; and use for the treatment or prevention of inflammatory diseases, diabetes, and malignant tumors.
NZ746950A (en) Heterocyclic gpr119 agonist compounds
TN2009000111A1 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CL2008001839A1 (en) Compounds derived from 2,7-diazaspirocycles, inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1; pharmaceutical composition comprising said compounds; Useful to treat obesity, diabetes, glucose intolerance, type II diabetes, among other diseases.
DE602007007473D1 (en) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
MX2012000704A (en) Gpr119 agonists.
CU20190056A7 (en) CARBOXYLIC ACIDS OF BENZIMIDAZOLES AND 4-AZA, 5-AZA, 7-AZA AND 4,7-DIAZA-BENZIMIDAZOLES AS GLP-1 RECEPTOR AGONISTS, USEFUL TO TREAT OR PREVENT CARDIOMETABOLIC DISEASES
TW200740799A (en) Alpha2C adrenoreceptor agonists
CL2007002890A1 (en) Compounds derived from 2-pyridinecarboxamide, glucosinase activator; pharmaceutical composition; and use of the compound for the treatment of diabetes or obesity.
CL2007001530A1 (en) Thiazole derived compounds, fbpase inhibitors; Preparation process; pharmaceutical composition; and use for the treatment and / or prophylaxis of diabetes mellitus type i, ii and iii, fasting glucose imbalance, glucose tolerance imbalance and diabetes complications.
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
MX2023005550A (en) Dichlorophenol hsd17b13 inhibitors and uses thereof.
TW200806311A (en) Neuropeptide-2 receptor-agonists
EP4596044A3 (en) Combination therapy of gpr119 agonists and dpp-4 inhibitors
CR20230452A (en) Incretin analog-containing compositions and uses thereof
MX2022013175A (en) NOVEL PROTEIN CONJUGATE, AND USE THEREOF TO PREVENT OR TREAT NON-ALCOHOLIC STEATOHEPATITIS, OBESITY AND DIABETES.